JAK2-IN-7 NEW
| Price | $148 | $372 | $663 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-14 |
Product Details
| Product Name: JAK2-IN-7 | CAS No.: 2593402-36-7 |
| Purity: 98.71% | Supply Ability: 10g |
| Release date: 2024/11/14 |
Product Introduction
Bioactivity
| 名稱 | JAK2-IN-7 |
| 描述 | JAK2-IN-7, a selective inhibitor targeting Janus Kinase 2 (JAK2), exhibits inhibitory concentrations (IC50) of 3 nM for JAK2, 11.7 nM for SET-2 cells, and 41 nM for Ba/F3 V617F cells, indicative of its potency and selectivity. This compound demonstrates more than 14-fold selectivity against JAK1, JAK3, and FLT3, underlining its specificity. JAK2-IN-7 effectively induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in tumor cells, manifesting significant antitumor activities [1]. |
| 體外活性 | JAK2-IN-7 (compound 13ac), in concentrations ranging from 0-1000 nM for 2 hours, dose-dependently inhibits the phosphorylation of JAK2 and STAT5 in both SET-2 and Ba/F3-JAK2 V617F cells. Additionally, at 10-160 nM over 24 hours, it promotes cell cycle arrest at the G0/G1 phase, and at 0.05-1.6 μM for 2 hours, it induces apoptosis in SET-2 cells. Both the cell cycle arrest and apoptosis induction are concentration-dependent, confirming the compound's efficacy in modulating key cellular processes related to proliferation and survival. |
| 體內(nèi)活性 | JAK2-IN-7, administered orally at doses ranging from 15 to 60 mg/kg daily for 16 days, demonstrated strong antitumor activity, inhibiting tumor growth by 82.3% in the SET-2 xenograft model [1]. At doses between 30 and 60 mg/kg, it significantly reduced disease symptoms in a Ba/F3-JAK2V617F allograft model by normalizing spleen weight by 77.1%, outperforming Ruxolitinib [1]. These findings, derived from administering JAK2-IN-7 to a NOD/SCID mouse model inoculated with SET-2 cells, highlight its potential without noticeable weight changes in the animals. |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 250 mg/mL (543.96 mM), Sonication is recommended. |
| 關(guān)鍵字 | JAK2IN7 | JAK-2-IN-7 | JAK2 IN 7 |
| 相關(guān)產(chǎn)品 | Delgocitinib | Deucravacitinib | Fedratinib | RO8191 | Ruxolitinib | Tofacitinib Citrate | CEP-33779 | Ruxolitinib phosphate | JAK-IN-10 | Baricitinib | Tofacitinib | Ritlecitinib |
| 相關(guān)庫 | 抗肺癌化合物庫 | 抗胰腺癌化合物庫 | 經(jīng)典已知活性庫 | 表觀遺傳庫 | 激酶抑制劑庫 | 血管生成庫 | 抑制劑庫 | 已知活性化合物庫 | 抗肝癌化合物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3400.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/10mg |
VIP1Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-07-17 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY